Skip to main content

Mesoblast

Mesoblast Ltd is an Australian clinical-stage biopharmaceutical company developing allogeneic cellular medicines for inflammatory and degenerative diseases. The company utilizes its proprietary mesenchymal lineage cell technology to advance cell therapy candidates including Ryoncil (remestemcel-L) for steroid-refractory acute graft-versus-host disease (aGVHD) and rexlemestrocel-L for chronic heart failure. Main revenue drivers currently consist of milestone payments, research development grants, commercial licensing royalties, and product sales. Mesoblast targets pediatric oncologists, transplant specialists, cardiologists, clinical research centers, and patients across the United States, Europe, and Asia-Pacific. The company holds a market-leading global position in allogeneic mesenchymal cell therapy development. Headquartered in Melbourne, Victoria, Australia, Mesoblast Ltd is listed on the Australian Securities Exchange and the Nasdaq Stock Market.

4 of the funds FundTelligence covers report a position in Mesoblast.

Legal name
Mesoblast Ltd
Sector
Health Care
Country
Australia
Funds holding it
4

Funds holding Mesoblast

Loading...